



®

anemos
PITCH DECK

Anemos Management Sdn Bhd

Agenda

- Executive Summary
- Company Introduction
- Problem
- Market Size
- Our solution plan
- Customer Experience
- Product
- Business Model
- Competition
- Team
- Financials
- Investment
- Why Now
- Contact Us

- Appendix:
 - Valuation Report
 - Recognition
 - Track Record
 - Upstream & Midstream
 - R&D Partner



Executive Summary

- Anemos is a health biotech company, specialised in DNA & Cell based health solutions by Nobel Prize Winner Researcher & Scientist, with proven formula of prolonging longevity.
- Anemos is positioning our DNA and cell-based health solutions as a natural evolution in the ongoing pursuit of advanced healthcare and longevity
- We have global support and we own the Intellectual Property to provide this cutting age technology to Malaysia and Asia Pacific
- We are looking for Angel partners than believes our purpose and vision to raise USD 2million with a potential ROI of 11x and 85% IRR.



Who we are?

Anemos is a health biotech company, specialised in DNA & Cell based health solutions by Nobel Prize Winner Researcher & Scientist with proven formula of prolonging longevity.

Purpose

We exist to help mankind to live healthier, happier and purposeful.

Vision

100 million healthy and happy lives over 100 years of age

Mission


Lead ourselves, our clients & our industry to live a healthier, happier & purposeful life

Live a life that sleep, eat and breathe: strengthening & lengthening lives

Love ourselves, love our people, love our clients and love our world

Core Values

Leadership. Oneness. Value. Energy.




anemos




Pain Point

- Rising Healthcare Costs: Growing financial burden of healthcare
- Limited Advanced Treatments: Restricted access to cutting-edge medical technologies
- Focus on Preventive Healthcare: Trend towards wellness and disease prevention



Rising Healthcare Costs



Limited Advanced Treatments




Preventive Healthcare

Target Audience

- Demographics:
 - 25-50 (target young adults & entrepreneur),
 - Gender (male & female),
 - Income levels (RM3,000 above)
- Geographics:
 - Initially focusing on Malaysia and the Asia Pacific region.
- Behaviors:
 - Interest in health, wellness, and longevity;
 - openness to innovative medical solutions.
- Needs:
 - Prevention and treatment of age-related diseases, personalized healthcare solutions.



Market Size



Serviceable Available Market
RM 78.2 Billion



Market Size

Identify/profile the customer you cater to

- Demographics: 25-50 (likely adults & entrepreneur), gender (male & female), income levels (RM3,000 above)
- Geographics: Initially focusing on Malaysia and the Asia Pacific region.
- Behaviors: Interest in health, wellness, and longevity; openness to innovative medical solutions.
- Needs: Prevention and treatment of age-related diseases, personalized healthcare solutions.

Summary of the TAM data for the global biotechnology market:

- Market Size (2022): Estimated at USD 1.37 trillion.
- Growth Projection: Expected CAGR of 13.96% from 2023 to 2030.
- Drivers: Government support, modernized regulatory frameworks, personalized medicine, orphan drug formulations, and an influx of emerging biotech companies.
- Impact of COVID-19: Accelerated drug development and vaccine manufacturing, with significant revenue generation from mRNA vaccines.
- Applications: Expanding demand in agriculture, strong clinical trial pipeline, chronic disease treatments, fermentation technology advances, CAR T and TCR T-cell therapies, and advancements in DNA sequencing and nanobiotechnology.
- Market Size (2023): USD 1.55 trillion.
- Projected Market Size (2030): USD 3.88 trillion.

Reference:

<https://www.grandviewresearch.com/industry-analysis/biotechnology-market>



Summary of the Serviceable Available Market (SAM) in Malaysia:

- Total Health Expenditure (2021): RM78.2 billion, with RM45.2 billion from public and RM32.96 billion from private sources.
- Main Areas of Increase:
- Inpatient services: RM6.06 billion.
- Pharmaceuticals: RM3.9 billion.
- Other areas (medical appliances, TCAM, etc.): RM848 million, RM518 million, RM1.8 billion respectively.
- Private Healthcare Beneficiaries:
- Private hospitals: RM11.42 billion.
- Private medical clinics: RM4.6 billion.
- Community pharmacies: RM3.9 billion.

Reference:

<https://codeblue.galencentre.org/2023/02/24/report-malysias-out-of-pocket-expense-rises-with-higher-spending-on-drugs-inpatient-services/#:~:text=Overall%2C%20Malaysia%20spent%20a%20total,57.9%20per%20cent%20or%20RM45.>

Summary of the Serviceable Obtainable Market (SOM) for Anemos in Malaysia

- Focused Market Segment: RM9.96 billion (RM6.06 billion from inpatient services + RM3.9 billion from pharmaceuticals).
- Assumed Market Share: If Anemos can capture a conservative 1% of this segment, due to factors like competition and market penetration challenges, the SOM would be approximately RM99.6 million.

Our Solution

Our Prediction, Precision, Prevention, Protection Personalised Solution Plan

100DNA

(Big data analysis)
1,099 gene test,
Provide a thorough reporting for preventive measures to maximise everyone potential to live healthily pass 100 years old.

100RX

Personalised pharmacy:
Based on 100DNA, provide a customised medication formula in a single dosage.

100AGELESS

Redefine the essence of aging gracefully

100CELLBANK

Cell banking solution, promote longevity

Enhancement programme:

- Health program
- Mental enhancement
- Leadership
- Spiritual
- And more

Healthy Entertainment

- Music
- Edutainment
- Travel
- Voluntourism
- Charity
- Environment
- Social events
- Parent child
- Silver Hair
- Sports/e-Sports



Tech Solution

- Personalized Healthcare: Offering solutions tailored to individual genetic profiles, leading to more effective and personalized treatments.
- Innovative Solutions: Leveraging cutting-edge research in DNA and cell-based technologies to offer advanced health solutions and longevity.
- Expertise: Backed by Nobel Prize-winning research from Professor Carl Zhang, ensuring credibility and high scientific standards.
- Preventive Approach: Emphasizing prevention of age-related diseases, aligning with the growing trend in healthcare.

100DNA



100AGELESS

COMING SOON

100CELLBANK

COMING SOON



100RX



Assesment

Just submit medical history such as blood test report etc

1



Specific Dosages:

Compounded supplements may be created with specific dosages or combinations of ingredients.

3



Customised Formulations:

Personalised formulations tailored to an individual's unique needs by 100RX.

2



Prescription Requirement:

In some cases, compounded supplements may require a prescription from 100RX's team.

4




Price

The average price of the supplement will be cheaper than the various branded products

5



100DNA



Powered by  **anemos**




Unlock the secrets of your genetic blueprint with the world's most comprehensive DNA test, providing you with over 1,099 reports to gain deep insights into your health and well-being.

- ✓ **Personalized Health Risk Assessment**
- ✓ **Optimal Diet, Fitness, and Wellness Insights**
- ✓ **Future Family Planning**
- ✓ **Prescription Drug Response**



100DNA with 100Entrepreneurs




100CELLBANK

- Immune cells are cells involved in or associated with the immune response and are commonly referred to as leukocytes.
- The human body is composed of approximately 60 trillion cells.
- Immune cells are a very useful tool in the prevention and treatment of cancer in humans.

Benefits to store immune cells

1. Treatment of malignant tumors/Cancer
2. Anti-Aging
3. Regulating Sub-health
4. Boosting immunity
5. Aesthetic




Why Now

By understanding the historical context and recent trends in biotechnology, Anemos is positioning our DNA and cell-based health solutions as a natural evolution in the ongoing pursuit of advanced healthcare and longevity. This historical perspective also demonstrates the company's alignment with the current trajectory of medical science and technology.

Define recent trends that make your solution possible

- Genetic Testing Access: Increased availability and affordability of genetic testing for identifying potential beneficiaries of telomere treatments.
- Telomere Biology: New insights into telomeres' role in aging and disease, leading to novel health interventions.
- Precision Medicine: Enhanced ability to customize treatments based on individual genetics.
- AI and Computing: Advanced AI and computing for in-depth genetic data analysis.



Reference: https://en.wikipedia.org/wiki/Timeline_of_biotechnology



Business Model

Revenue model

Anemos' revenue is projected to increase annually from RM 47,671,000 in 2024 to RM 178,890,000 in 2028. This growth indicates a model based on expanding sales or services in the health biotech sector.

Pricing

- 100RX - Average RM1,200 per consumer quarterly
- 100DNA - RM2,998

Average account size and/or lifetime value

- The annual spend for the 100RX personalized supplement is RM 4,800 (RM 1,200 monthly x 4quarters).
- Adding the one-time cost of the 100DNA genetic test at RM 2,998, the average revenue per customer (assuming a one-year relationship) is RM 6,598.

Sales & distribution model

- Network and Online Digital Marketing: Utilizes digital channels like social media, email, and online advertising to reach potential customers. (Example: 100Women, 100CEO Fitness, Arising Nation)
- Collaboration Partners: Partners with relevant businesses or organizations to expand market reach and customer access. (Example: 10X Strategy Coach Platform)
- Offline Health Talks: Conducts educational and promotional events to engage with customers and raise awareness about the products and services offered.



Competition

MJ Health as a Competitor:

- Established Presence: Operational since 2007 in Malaysia, indicating market familiarity and customer trust.
- Comprehensive Health Programs: Focus on preventive health, encompassing physical and mental well-being.
- Health Management Platform: Covers various phases from screening to intervention, appealing to health-conscious individuals.
- Philosophy and Core System: Emphasizes a holistic approach to health (live longer, stay healthier, age gracefully) supported by an efficient system (AMHTS).

Competitive Advantages of Anemos:

- Specialization in DNA and Cell-Based Solutions: Differentiates from MJ Health's general preventive health approach.
- Nobel Prize-Backed Research: Adds credibility and scientific edge.
- Focus on Aging and Age-Related Diseases: Directly addresses growing concerns about aging, offering potentially unique solutions.
- Personalized Medicine: Tailored treatments based on genetic profiles, aligning with current medical trends.
- Global Ambition: Aims for a broader impact, potentially reaching beyond the Malaysian market.

CircleDNA as a Competitor:

- Product Offering: Non-invasive, at-home DNA testing with over 500 reports for health insights.
- Healthcare Approach: Focus on preventive healthcare, understanding genetic risks for diseases, and personal well-being.
- Expertise: Developed by leaders in DNA sequencing and genomics.
- Privacy and Data Security: Emphasis on customer privacy in handling DNA information.
- Global Reach: A large community of users, indicating widespread acceptance and market penetration.

Competitive Advantages of Anemos:

- Specialization in Telomere Technology: Direct focus on aging and cellular health.
- Research-Driven Approach: Backed by Nobel Prize-winning research, offering credibility.
- Comprehensive Health Solutions: Beyond genetic testing, offering DNA and cell-based health solutions.
- Targeting Specific Health Issues: Focused on age-related diseases and personal health management.
- Personalized Solution: Anemos provides tailored treatments and supplements, focusing on individual health needs based on genetic profiles, enhancing proactive health management.

<https://mjhealthscreening.com/our-story/>
<https://circledna.com/en/about-us>




Financial Roadmap

Timing Round	March 2024 Angel Round	March 2025 Series A Round	March 2026 Series B Round	March 2028 IPO
A. Valuation				
Pre-money	US\$ 18,000,000	US\$ 45,000,000	US\$ 100,000,000	US\$ 300,000,000
MYR	RM 81,000,000.00	RM 202,500,000.00	RM 450,000,000.00	RM 1,350,000,000.00
Capital Injection	US\$ 2,000,000	US\$ 5,000,000	US\$ 15,000,000	US\$ 50,000,000
MYR	RM 9,000,000.00	RM 22,500,000.00	RM 67,500,000.00	RM 225,000,000.00
Post-money	US\$ 20,000,000	US\$ 50,000,000	US\$ 115,000,000	US\$ 350,000,000
MYR	RM 90,000,000.00	RM 225,000,000.00	RM 517,500,000.00	RM 1,575,000,000.00
B. Shareholding % - Pre-money				
	100.0%	100.0%	100.0%	100.0%
Anemos	100.0%	90.0%	81.0%	70.4%
Angel Investors	0.0%	10.0%	9.0%	7.8%
Series A Investors	0.0%	0.0%	10.0%	8.7%
Series B Investors	0.0%	0.0%	0.0%	13.0%
IPO Investors	0.0%	0.0%	0.0%	0.0%
C. Shareholding % - Post-money				
	100.0%	100.0%	100.0%	100.0%
Anemos	90.0%	81.0%	70.4%	60.4%
Angel Investors	10.0%	9.0%	7.8%	6.7%
Series A Investors	0.0%	10.0%	8.7%	7.5%
Series B Investors	0.0%	0.0%	13.0%	11.2%
IPO Investors	0.0%	0.0%	0.0%	14.3%
4. IRR for Angel Investors				
Timing	31/03/2024	31/03/2025	31/03/2026	31/03/2028
Cashflow	US\$ (2,000,000)	US\$ -	US\$ -	US\$ 23,478,261
IRR	85%			
ROI	1173.91%			



Anemos Yearly Projection



Investment

We are looking for partners that believe in our Purpose
to help mankind to **live healthier, happier and purposeful.**

We aim to help 100 million people in Malaysia and Asia Pacific
to have a **healthier and happier lives over 100 years of age**

Pre-Money Valuation : USD 18 Million

Fund Raise Amount : USD 2 Million

Per lot : USD 250,000

Total Dilution : 10%

Potential ROI : 1173%

IRR : 85%



Cap Table

Cap Table

- Edmund Heng Guan Boon holds 1,560,000 shares. (72.23%)
- Yam Kah Chun holds 600,000 shares. (27.78%)

The deal

- LIFEKO Patent - Value RM8mil
- LIFEENE Patent - Value RM27mil

(Valuation is done by Adastra, refer to appendix)



Fund Utilization


USAGE OF FUND: USD 2,000,000 (RM9,000,000)

SALES & MARKETING: 50% (RM4,500,000)

CAPITAL EXPENDITURES: 20% (RM1,800,000)

OPERATION: 20% (RM1,800,000)

OVERSEAS DEVELOPMENT: 10% (RM900,000)



Financials

Exit Mechanism

- Either can redeem or convert on 5th year
- In the event of a trade sale or IPO, regardless of the year, the investor can decide to redeem or convert when Anemos go listed at NASDAQ




Why Now

By understanding the historical context and recent trends in biotechnology, Anemos is positioning our DNA and cell-based health solutions as a natural evolution in the ongoing pursuit of advanced healthcare and longevity. This historical perspective also demonstrates the company's alignment with the current trajectory of medical science and technology.

Define recent trends that make your solution possible

- Genetic Testing Access: Increased availability and affordability of genetic testing for identifying potential beneficiaries of telomere treatments.
- Telomere Biology: New insights into telomeres' role in aging and disease, leading to novel health interventions.
- Precision Medicine: Enhanced ability to customize treatments based on individual genetics.
- AI and Computing: Advanced AI and computing for in-depth genetic data analysis.



Reference: https://en.wikipedia.org/wiki/Timeline_of_biotechnology



VALUATION REPORT

CONCLUSION OF TECHNOLOGY VALUE

Based on the two values of the nutritional formula, we used an equal weightage to arrive at the final value of the nutritional formula as follows:

Royalty rates	Value of nutritional formula (RM million)	Weightage (%)	Weighted value (RM million)
7.5 per cent of sales	7.24	50	3.620
10.0 per cent of sales	9.65	50	4.825
Final value of nutritional formula		100	8.445

Based on our assessment, the value of the nutritional formula based on moringa as herbal detoxification product was estimated to be RM8.445 million.

We noted that the nutritional formula based on moringa as herbal detoxification product was in the growing sector of the nutraceuticals industry.


Based on these assumptions and using projection of sales of HPV packages, we calculated the value of the antiviral polysaccharide-based therapy for HPV as follows:

No.	Value of patent using RFR method	Value (RM Million)	Weightage	Proportionate value (RM Million)
1	Base Scenario	30.76	50%	15.38
2	Sensitivity Scenario	24.61	50%	12.31
Weighted value of antiviral polysaccharide-based therapy for HPV (RM million)				27.69
Rounded-off				27.7

The details of the estimation of the value of the antiviral polysaccharide-based therapy for HPV are shown in the Attachments.

Valuation

The valuation displayed below is the result of the weighted average of different methods. The use of several methods is a best practice in company valuation, as looking at the business from different perspectives results in a more comprehensive and reliable view. These methods are compliant with IPEV (International Private Equity Valuation) Guidelines and each of them will be explained in more detail in the following pages of the report. More information on the weights can be found in the Appendix.



Patent LIFEKO

Patent LIFEGENE

App







Recognition

CHINA STATE-OWNED ENTERPRISE CERTIFICATION

The Evaluation by China Technology Exchange



anemos





Recognition

CHINA STATE-OWNED ENTERPRISE CERTIFICATION



anemos

Main Certificates



Recognition

GERMAN CERTIFICATION



3M Solutions
SAFETY DATA SHEET
 warning: H373, H374, H375

SECTION 1: IDENTIFICATION
 Product Name: Careless™
 Other Names and Address: VITAL SOLUTIONS SWISS AG, Industriestrasse 10, 8600 Muri (CH)

SECTION 2: HAZARD IDENTIFICATION
 NONE

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS
 CHEMICAL INFORMATION: Single lingui (Singapore, India)

SECTION 4: FIRST AID MEASURES
 In case of contact with skin: Wash immediately with copious amount of drinking water. Wash affected areas of clothes.

SECTION 5: FIRE FIGHTING MEASURES
 Nothing specific

SECTION 6: ACCIDENTAL RELEASE MEASURES
 Avoid dust formation.

SECTION 7: HANDLING AND STORAGE
 STORAGE: Store in original unopened and sealed in original container. Keep away from sunlight, avoid heat and dry conditions and avoid contamination.

SECTION 8: EXPOSURE CONTROL/PERSONAL PROTECTION
 If dust formation caused by handling occur to avoid breathe apparatus for places with high concentration. Always wear protective clothing and use the ventilation.

The Address: Swiss AG, Industriestrasse 10, Muri, Switzerland, Phone +41(0)56 381 01 01, Fax +41(0)56 381 01 00, www.vital-solutions.com

3M Solutions
SAFETY DATA SHEET
 warning: H373, H374, H375

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES
 Appearance: Clear liquid
 Odor: Characteristic
 pH-Value: 4.5
 Melting Point: 10°C

SECTION 10: STABILITY AND REACTIVITY
 Mixtures to avoid: None of them for standard purposes.

SECTION 11: TOXICOLOGICAL INFORMATION
 NONE

SECTION 12: ECOLOGICAL INFORMATION
 Biodegradable: Not available

SECTION 13: DISPOSAL INFORMATION
 Nothing specific

SECTION 14: TRANSPORT INFORMATION
 Not applicable

SECTION 15: REGULATORY INFORMATION
 Specific of Single lingui: Singapore, India

SECTION 16: OTHER INFORMATION
 This information is based on current best of knowledge related to the product and the user should be advised to regularly check for updates from the department of safety requirements and to be assessed to guarantee any particular protection.

The Address: Swiss AG, Industriestrasse 10, Muri, Switzerland, Phone +41(0)56 381 01 01, Fax +41(0)56 381 01 00, www.vital-solutions.com

3M Solutions
SAFETY DATA SHEET
 warning: H373, H374, H375

SECTION 17: PHYSICAL AND CHEMICAL PROPERTIES
 Appearance: Clear liquid
 Odor: Characteristic
 pH-Value: 4.5
 Melting Point: 10°C

SECTION 18: STABILITY AND REACTIVITY
 Mixtures to avoid: None of them for standard purposes.

SECTION 19: TOXICOLOGICAL INFORMATION
 NONE

SECTION 20: ECOLOGICAL INFORMATION
 Biodegradable: Not available

SECTION 21: DISPOSAL INFORMATION
 Nothing specific

SECTION 22: TRANSPORT INFORMATION
 Not applicable

SECTION 23: REGULATORY INFORMATION
 Specific of Single lingui: Singapore, India

SECTION 24: OTHER INFORMATION
 This information is based on current best of knowledge related to the product and the user should be advised to regularly check for updates from the department of safety requirements and to be assessed to guarantee any particular protection.

The Address: Swiss AG, Industriestrasse 10, Muri, Switzerland, Phone +41(0)56 381 01 01, Fax +41(0)56 381 01 00, www.vital-solutions.com

3M Solutions
SAFETY DATA SHEET
 warning: H373, H374, H375

SECTION 25: PHYSICAL AND CHEMICAL PROPERTIES
 Appearance: Clear liquid
 Odor: Characteristic
 pH-Value: 4.5
 Melting Point: 10°C

SECTION 26: STABILITY AND REACTIVITY
 Mixtures to avoid: None of them for standard purposes.

SECTION 27: TOXICOLOGICAL INFORMATION
 NONE

SECTION 28: ECOLOGICAL INFORMATION
 Biodegradable: Not available

SECTION 29: DISPOSAL INFORMATION
 Nothing specific

SECTION 30: TRANSPORT INFORMATION
 Not applicable

SECTION 31: REGULATORY INFORMATION
 Specific of Single lingui: Singapore, India

SECTION 32: OTHER INFORMATION
 This information is based on current best of knowledge related to the product and the user should be advised to regularly check for updates from the department of safety requirements and to be assessed to guarantee any particular protection.

The Address: Swiss AG, Industriestrasse 10, Muri, Switzerland, Phone +41(0)56 381 01 01, Fax +41(0)56 381 01 00, www.vital-solutions.com

DECLARATION
 WE HEREBY CERTIFY THAT THE FOLLOWING PRODUCT LISTED BELOW:
 PRODUCT NAME: CARELESS™
 MANUFACTURED BY: VITAL SOLUTIONS SWISS AG

IS FREE FROM THE FOLLOWING FOOD ALLERGENS: SOY, DATE, FENUGREEK, MUSTARD, SESAME SEEDS, SULFITES, TREE NUTS, WHEAT, WHEAT GLUTEN, CORN, NUTRITIONAL YEAST, BEANS, BEANS SEEDS, BEANS SEEDS GERM, LAMINATED MILK, MILK, MILK ALBUMEN, MILK ALBUMEN GERM AND AN ANIMAL ORIGIN DERIVED PRODUCT.

WE FULLY UNDERSTAND THE IMPORTANCE AND ACCURACY OF THIS STATEMENT.

April 8, 2014
 D. K. Sagar Sivan, Head of Quality

The Address: Swiss AG, Industriestrasse 10, Muri, Switzerland, Phone +41(0)56 381 01 01, Fax +41(0)56 381 01 00, www.vital-solutions.com

DECLARATION
 WE HEREBY CERTIFY THAT THE FOLLOWING PRODUCT LISTED BELOW:
 PRODUCT NAME: CARELESS™
 MANUFACTURED BY: VITAL SOLUTIONS SWISS AG

IS FREE FROM THE FOLLOWING FOOD ALLERGENS: SOY, DATE, FENUGREEK, MUSTARD, SESAME SEEDS, SULFITES, TREE NUTS, WHEAT, WHEAT GLUTEN, CORN, NUTRITIONAL YEAST, BEANS, BEANS SEEDS, BEANS SEEDS GERM, LAMINATED MILK, MILK, MILK ALBUMEN, MILK ALBUMEN GERM AND AN ANIMAL ORIGIN DERIVED PRODUCT.

WE FULLY UNDERSTAND THE IMPORTANCE AND ACCURACY OF THIS STATEMENT.

April 8, 2014
 D. K. Sagar Sivan, Head of Quality

The Address: Swiss AG, Industriestrasse 10, Muri, Switzerland, Phone +41(0)56 381 01 01, Fax +41(0)56 381 01 00, www.vital-solutions.com

DECLARATION
 WE HEREBY CERTIFY THAT THE FOLLOWING PRODUCT LISTED BELOW:
 PRODUCT NAME: CARELESS™
 MANUFACTURED BY: VITAL SOLUTIONS SWISS AG

IS FREE FROM THE FOLLOWING FOOD ALLERGENS: SOY, DATE, FENUGREEK, MUSTARD, SESAME SEEDS, SULFITES, TREE NUTS, WHEAT, WHEAT GLUTEN, CORN, NUTRITIONAL YEAST, BEANS, BEANS SEEDS, BEANS SEEDS GERM, LAMINATED MILK, MILK, MILK ALBUMEN, MILK ALBUMEN GERM AND AN ANIMAL ORIGIN DERIVED PRODUCT.

WE FULLY UNDERSTAND THE IMPORTANCE AND ACCURACY OF THIS STATEMENT.

April 8, 2014
 D. K. Sagar Sivan, Head of Quality

The Address: Swiss AG, Industriestrasse 10, Muri, Switzerland, Phone +41(0)56 381 01 01, Fax +41(0)56 381 01 00, www.vital-solutions.com

DECLARATION
 WE HEREBY CERTIFY THAT THE FOLLOWING PRODUCT LISTED BELOW:
 PRODUCT NAME: CARELESS™
 MANUFACTURED BY: VITAL SOLUTIONS SWISS AG

IS FREE FROM THE FOLLOWING FOOD ALLERGENS: SOY, DATE, FENUGREEK, MUSTARD, SESAME SEEDS, SULFITES, TREE NUTS, WHEAT, WHEAT GLUTEN, CORN, NUTRITIONAL YEAST, BEANS, BEANS SEEDS, BEANS SEEDS GERM, LAMINATED MILK, MILK, MILK ALBUMEN, MILK ALBUMEN GERM AND AN ANIMAL ORIGIN DERIVED PRODUCT.

WE FULLY UNDERSTAND THE IMPORTANCE AND ACCURACY OF THIS STATEMENT.

April 8, 2014
 D. K. Sagar Sivan, Head of Quality

The Address: Swiss AG, Industriestrasse 10, Muri, Switzerland, Phone +41(0)56 381 01 01, Fax +41(0)56 381 01 00, www.vital-solutions.com



Recognition

SINGAPORE CERTIFICATION



anemos

 Agi-Food & Veterinary Authority of Singapore <small>35, Loring Avenue Road #1417 Singapore 48503</small>	
REGISTRATION TO IMPORT PROCESSED FOOD PRODUCTS AND FOOD APPLIANCE	
Name of Licensee HONG TEE COOK	Import Entry No. 33377654
Business/Company Name & Address OS DEPRE	Expiry Date 29/02/2020
13 STOCK RESERVE VIEW #02-03 ALAMARU @ THE PARK SINGAPORE 439721	
<p>The license may import processed food and food appliances subject to the following conditions:</p> <ol style="list-style-type: none"> The licensee shall obtain approval from the Director General, Agriculture and Veterinary Services for the import of such category processed food and food appliances. The import of processed food and food appliances is subject to comply with the laws of food and food packaging regulations. All food products are to conform to the regulations in force. The Director General, Agriculture and Veterinary Services may restrict or prohibit the import of any food products or food appliances which do not conform to the laws of processing and packaging. All components of food products are to conform to the laws of food and food packaging regulations. Labels on all the products of the company have been stamped by the licensee and comply with the regulations and standards in force. The Director General, Agriculture and Veterinary Services may at any time vary or revoke the validity conditions or import conditions. The Regulations to import processed food and food appliances may be suspended or amended if the above conditions is complied with or an alternative compliance under the laws of food and food packaging. 	
Licence No.: IP1980548	
 TO DIRECTOR GENERAL, AGRICULTURE AND VETERINARY SERVICES	

 Agi-Food & Veterinary Authority of Singapore <small>35, Loring Avenue Road #1417 Singapore 48503</small>	
REGISTRATION TO IMPORT PROCESSED FOOD PRODUCTS AND FOOD APPLIANCE	
Name of Licensee OS DEPRE	Import Entry No. 33377654
Business/Company Name & Address OS DEPRE	Expiry Date 29/02/2020
13 STOCK RESERVE VIEW #02-03 ALAMARU @ THE PARK SINGAPORE 439721	
<p>The license may import processed food and food appliances subject to the following conditions:</p> <ol style="list-style-type: none"> The licensee shall obtain approval from the Director General, Agriculture and Veterinary Services for the import of such category processed food and food appliances. The import of processed food and food appliances is subject to comply with the laws of food and food packaging regulations. All food products are to conform to the regulations in force. The Director General, Agriculture and Veterinary Services may restrict or prohibit the import of any food products or food appliances which do not conform to the laws of processing and packaging. All components of food products are to conform to the laws of food and food packaging regulations. Labels on all the products of the licensee have been stamped by the licensee and comply with the regulations and standards in force. The Director General, Agriculture and Veterinary Services may at any time vary or revoke the validity conditions or import conditions. The Regulations to import processed food and food appliances may be suspended or amended if the above conditions is complied with or an alternative compliance under the laws of food and food packaging. 	
Licence No.: IP18A0357	
 TO DIRECTOR GENERAL, AGRICULTURE AND VETERINARY SERVICES	

 HFCE	
المجلس الأوروبي للحلال Halal Food Council of Europe	
4 Rue de la Presse, 1050 Brussels, Belgium - Tel: +32 (0)27 014, +32 (0)27 2108 - Fax: +32 (0)27 2141 - www.hfce.be Registration No. 4078648	
شهادة حلال HALAL CERTIFICATE	
المجلس الأوروبي للحلال يشهد بأن المنتجات المذكورة أدناه Halal Food Council of Europe hereby certifies that the products listed below have met the Halal requirements in accordance with the Islamic Law.	
Date Certificate issued July 4, 2019	Certificate No. KUL.BN.009.0096.18001.DE
Company Name & Address: Manly, Naturaprodukt GmbH & Co. KG Am der Sandgrube Reichenhausen, GERMANY	
Name of Product:	1. Mango Powder (Candied)
Valid until: June 22, 2016	
 Prof. Dr. H. Mohamed Saïd Director	

 KEMENTERIAN KESIHATAN MALAYSIA MINISTRY OF HEALTH MALAYSIA	
SIJIL GMP GMP CERTIFICATE (Good Manufacturing Practices)	
Kementerian Kesihatan Malaysia dengan ini mengisytiharkan bahawa Ministry of Health Malaysia hereby certifies that	
NGS HEALTHCARE (M) SDN BHD NO 11 JALAN PTP 12 TAMAN PERINDUSTRIAN TAMPIN PERDANA 4700 PECHONG SELANGOR MALAYSIA	
telah mematuhi syarat-syarat GMP dalam pengeluaran sediaan GMP has fulfilled the conditions for implementation of GMP system	
	
NOLANI BINTI BAYAT NOROD OTHMAN Pengerusi Kesihatan Kualiti dan Kualiti Makanan Director of Food Safety and Quality Kementerian Kesihatan Malaysia Ministry of Health Malaysia	
Certificate No. 19-AM-0237	Issue Date 22 June 2017
Expiry Date 21 June 2020	





anemos

CONTACT US

Block D, Kelana Square, D-9-10,
17, Jalan SS 7/26, 47301 Petaling Jaya, Selangor

<https://anemos-global.co>

